Hoffmann-La Roche posts results of Phase 3 obinutuzumab trial in childhood nephrotic syndrome
The study, completed in September 2025, enrolled 85 participants aged 2-25 years and compared obinutuzumab with mycophenolate mofetil. Results were first posted on ClinicalTrials.gov on October 14, 2026.
Primary source
ClinicalTrials.gov results record, October 14, 2026
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
Read the source: A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation